SOURCE: EVCARCO

EVCARCO

February 22, 2012 09:30 ET

EVCARCO, Inc. Signs a Memorandum of Understanding With HFX, Inc.

FORT WORTH, TX--(Marketwire - Feb 22, 2012) - EVCARCO, Inc. (OTCBB: EVCA) (OTCQB: EVCA) announced today that the Company has signed a Memorandum of Understanding (MOU) with HFX Laboratories, Inc. regarding the market development, testing and licensing of the HFX4 Hydrogen Hybrid Combustion/Fuel Enhancement Systems.

EVCA will establish retail distribution for the HFX4 System through its dealerships and showrooms upon completion of Due Diligence. The HFX4 Hybrid System is a unique product that produces hydrogen gas for use as a catalyst in the vehicle's combustion system. The hydrogen catalyst is introduced into the vehicle's air intake to completely utilize the fuel in the combustion process.

Mack Sanders, CEO of EVCARCO, remarked, "With gasoline prices reaching $4.00 a gallon in some areas and projected to go higher, the HFX4 System is a perfect fit for after-market vehicles. The HFX4 Hybrid System seems to be easy to install on an existing vehicle, improves performance, and claims to provide an increase in MPG and reduction in emissions. Upon completion of the Due Diligence, a Definitive Licensing Distribution Agreement will be entered into for the U.S., Canada, Mexico and Russia. The goal is to find in our Due Diligence, results of 20% to 35% improvement in MPG and a reduction in emissions in the range of 60% depending on engine efficiency

For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.

EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles from multiple manufactures. EVCARCO - Future Driven ®

This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Contact Information

  • Investor Relations Contact:
    Jack Eversull
    The Eversull Group, Inc.
    972-571-1624
    214-469-2361 fax
    Email Contact